Cargando…
Nrf2在EGFR基因突变肺腺癌中的表达及其与EGFR-TKIs疗效间的相关性研究
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become first-line treatment drugs for lung adenocarcinoma patients with EGFR gene mutations. Significant interindividual variations in response rate, progression-free survival (PFS), and overall su...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000052/ https://www.ncbi.nlm.nih.gov/pubmed/24581168 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.02.15 |